Will Offering a Blood Test to Detect Lung Cancer Improve Screening Rates?
“Dr. Melinda Aldrich wants to boost screening rates to catch lung cancer earlier when it is more treatable.”
Tuberculosis, Chronic Bronchitis Linked to Lung Cancer Risk in Never-Smokers
“A literature search was performed in PubMed and Embase from inception to July 2025 for relevant studies that assessed associations between previous lung disease and LC risk in adults aged 18 years and older who had never smoked. The primary outcome was LC risk in populations with or without a history of TB, asthma, or CB.”
First ever inhalable gene therapy for cancer gets fast-tracked by FDA
“A gene therapy that patients breathe in has been found to shrink lung tumours by inserting immune-boosting genes into surrounding cells”
Inhibition of primary ciliogenesis enhances efficacy of EGFR‑TKIs against non‑small cell lung cancer cells
“Primary cilia are antenna‑like organelles on almost all human cells that sense and transduce extracellular cues into cellular response. Primary cilia have been reported to be implicated in drug resistance in several cancer types, but their roles in cellular response to epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors (TKIs) in non‑small cell lung cancer (NSCLC) are still not fully understood.”
Boots launches lung cancer early awareness scheme
“Signs will be placed around over-the-counter cold and flu management products advising patients to speak to a Macmillan-trained pharmacist if they have symptoms suggestive of lung cancer.”
UV-induced immune modulation in the lung niche slows cancer progression
“Ultraviolet radiation has a well-documented local immunosuppressive effect on the skin that can enhance subcutaneous tumor growth; however, its systemic impact on cancer progression in internal organs remains poorly understood. Here, we show that chronic UVB exposure after melanoma metastasis to the lung inhibits metastatic growth and modestly improves survival in mice.”
Lilly’s Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
“INDIANAPOLIS, Feb. 16, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo. The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in investigator-assessed event-free survival (EFS) in patients with early-stage (II-IIIA) rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC).”
Video:
Precision Oncology: Transforming Survival in Lung Cancer Brain Metastases
“The landscape of treating brain metastases—cancer that has spread to the brain—is undergoing a radical shift from a terminal prognosis to a manageable chronic condition. Manmeet Ahluwalia, MD, chief scientific officer at Baptist Health Miami Cancer Institute, highlights that while these diagnoses were once associated with a survival rate of only 6 to 12 months, modern innovations now allow many patients to live for 3 to 5 years or longer.”
FDA Issues 510(k) Clearance of AI-Powered Assessment for Lung Cancer on Low-Dose CT Scans
“The Food and Drug Administration (FDA) has granted 510(k) clearance for the AI-enabled eyonis® LCS software, which may facilitate earlier detection of lung cancer on low-dose computed tomography (CT) scans.”
